The methylation industry is transforming, but legacy methods like microarrays and bisulfite sequencing still lack the sensitivity for clinical integration, hindering biomarker discovery and clinical impact. Wasatch BioLabs’ Direct Whole Methylome Sequencing (dWMS) delivers a comprehensive solution, offering whole genome sequencing and methylation analysis with unmatched quality and flexibility.
Designed to meet the needs of research and biomarker discovery, dWMS delivers scalable multi-omic solutions to advance assay development, epigenetic studies, and beyond.
Traditional methylation technologies leave researchers guessing—are regions uniformly 10% methylated, or is methylation concentrated in just 10% of the region?
Wasatch BioLabs’ dWMS service resolves this uncertainty. By analyzing over 96% of CpGs across the genome, dWMS captures the full methylation context across entire DNA molecules with native reads, enabling precise, molecule-level analyses.
Capturing 30X more CpG sites and 2X more CpG islands without bisulfite or amplification biases, researchers gain a comprehensive view of methylation, hydroxymethylation, and DNA sequence—all in a single run.
dWMS identifies 2.4x more differentially methylated CpG islands (CGIs) than traditional microarrays. gDNA was extracted from Tissue 1 (n=4) and Tissue 2 (n=4) and analyzed with both methylation array and dWMS. dWMS captured 2.4 times more CGIs containing significant differential methylation between the two tissues, including 91% of those detected by the array.
dWMS data enables bioinformatic identification of cell-type-specific methylation signatures and cell-of-origin from complex multi-CpG patterns. gDNA was extracted from Tissue 1 (n=1) and two purified cell types (Type 1, n=1; Type 2, n=1), then sequenced with dWMS. A representative 101 bp differentially methylated region highlights methylation patterns unique to Cell Type 2. Each ONT track represents single reads: red marks methylated sites, blue unmethylated.
Leveraging nanopore sequencing, dWMS long reads resolve repetitive regions, structural variants, phasing, and other complex genomic features. This capability enhances genome assemblies, reveals complex regulatory elements, and provides deeper insights into genomic architecture.
As an ecosystem-driven platform, dWMS overcomes the limitations of legacy methylation technologies, enabling the seamless transition from biomarker discovery to clinical applications—all on one platform.
To support genome assembly studies, Wasatch BioLabs offers three scalable solutions that deliver assembled genome DNA sequence and methylation data: moderate-coverage draft genomes for gene discovery, ultra-long-read chromosome-level assemblies for resolving complex regions, and advanced assemblies integrating RNA sequencing for functional insights. These unbiased, high-quality de novo assemblies accommodate any species and genome length, leveraging long reads to resolve complex regions with precision.
